LIDDS
ABOUT
TECHNOLOGY
PIPELINE
INVESTORS
NEWS AND MEDIA
CONTACT

LIDDS
ABOUT
TECHNOLOGY
PIPELINE
INVESTORS
NEWS AND MEDIA
CONTACT

News and media

Newsroom

This is LIDDS newsroom. Here you can find our pressrelease archive, financial calendar archive, events & presentation archive, logos and high res images for press.

press

Press releases

All
Regulatory
Non Regulatory

2022-01-14 LIDDS presenterar vid Redeye Fight Cancer seminarium
2022-01-14 LIDDS presents at Redeye Fight Cancer Seminar
2022-01-11 LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
2022-01-11 LIDDS announces successful stage 1 in R&D project

2022-01-11 LIDDS announces successful stage 1 in R&D project
2022-01-11 LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
2021-12-20 LIDDS utser Matthew Lindon till Chief Scientific Officer
2021-12-20 LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer

2022-01-14 LIDDS presents at Redeye Fight Cancer Seminar
2022-01-14 LIDDS presenterar vid Redeye Fight Cancer seminarium
2021-12-17 LIDDS patent covering the NanoZolid® production process granted in China
2021-11-17 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS

Please note that LIDDS will disclose information in Press releases only in English going forward.

Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska.

events

Events

Aktiespararna, Småbolagsdagarna den 8 juni, 2021, Nina Herne, CEO
Redeye Growth Day, 2 juni 2021, Nina Herne, CEO
Redeye Life Science Day, November 26 2020, Monica Wallter, CEO
Erik Penser temadag med bolag i cancerforskningens frontlinje, Stockholm, October 6, 2020, Monica Wallter, CEO

presentations

Presentations

Redeye interview with CEO, Nina Herne, November 30, 2021
Interview with CEO, Nina Herne, May 2021
CEO interview at Redeye on April 15
Monica Wallter interview with Finwire March 31, 2021

analysis

Company Analysis

Stockpicker Company Analysis January 13, 2020 - Link to analysis
Avanza’s analysis December 11 2019 - Link to analysis
Redeye’s Company Analysis December 6, 2019 - Link to analysis
Redeye’s company analysis 23 April 2019 - Link to analysis

Photo Library

NanoZolid logo pack
© LIDDS AB

Lidds logo pack – Dark Cerulean
© LIDDS AB

LIDDS logo pack – White
© LIDDS AB

Lidds logo pack – Black
© LIDDS AB

LIDDS labratory
© LIDDS AB

Product image
© LIDDS AB

Nina Herne
© LIDDS AB

Jenni Björnulfson
© LIDDS AB

Stefan Grudén
© LIDDS AB

Niklas Axén
© LIDDS AB

Martin Johansson
© LIDDS AB

Charlotta Gauffin
© LIDDS AB

Erwin Brenndörfer
© LIDDS AB

Jan Törnell
© LIDDS AB

David Bejker
© LIDDS AB

Daniel Lifveredson
© LIDDS AB

IngaLill Forslund Larsson
© LIDDS AB

Maria Forss
© LIDDS AB

Anders Bjartell
© LIDDS AB

Video Library

lidds-2020-12-21-16_34_47.mp4
© LIDDS AB

lidds2-2021-03-24-10_00_11.mp4
© LIDDS AB

Lidds

LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.

Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com

Financial Calendar

2022-01-20 Presentation at Redeye Fight Cancer Seminar
2022-02-23 Year-end Report 2021
2022-04-26 Annual report 2021
2022-05-24 Interim report Jan – Mar 2022
2022-06-01 Annual General Meeting of Shareholders
2022-08-25 Interim report Jan – Jun 2022
2022-11-24 Interim report Jan – Sep 2022

Subscribe for news

Press releases

All
Regulatory
Non Regulatory

2022-01-14 LIDDS presenterar vid Redeye Fight Cancer seminarium
2022-01-14 LIDDS presents at Redeye Fight Cancer Seminar
2022-01-11 LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
2022-01-11 LIDDS announces successful stage 1 in R&D project

2022-01-11 LIDDS announces successful stage 1 in R&D project
2022-01-11 LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
2021-12-20 LIDDS utser Matthew Lindon till Chief Scientific Officer
2021-12-20 LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer

2022-01-14 LIDDS presents at Redeye Fight Cancer Seminar
2022-01-14 LIDDS presenterar vid Redeye Fight Cancer seminarium
2021-12-17 LIDDS patent covering the NanoZolid® production process granted in China
2021-11-17 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS

LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Powered by GDPR plugin

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Cookie Policy

More information about our Cookie Policy

More information about our Privacy Policy